MICA: Assessing the therapeutic efficacy of 11beta-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension

Lead Research Organisation: University of Birmingham
Department Name: Clinical and Experimental Medicine

Abstract

Idiopathic intracranial hypertension (IIH), a condition of raised brain pressure, is a common cause of blindness in young overweight women. The underlying cause of the condition has not been fully established and the best way to treat IIH is not known. Drugs such as acetazolamide, have not been shown to be effective and additionally have intolerable side effects. Brain fluid shunting surgery can be used to save vision, but shunts block in over half of patients and therefore need replacing, often multiple times. Treatments such as weight loss are notoriously difficult. Our recent research has highlighted the potential role of an enzyme that generates steroid locally in brain tissues. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) generates active steroid within the parts of the brain that produce cerebrospinal fluid (CSF) - the fluid that bathes the brain. Production of too much CSF can lead to increased brain pressure in IIH and we believe that 11beta-HSD1 drives this process in IIH. Additionally, we have demonstrated that weight loss and brain pressure reduction which significantly improve IIH also reduced 11beta-HSD1 activity. We therefore suggest that reducing 11beta-HSD1, with an oral tablet of AZD4017 (an inhibitor of 11beta-HSD1 developed by AstraZeneca) may represent a landmark treatment for IIH.
Through a partnership between AstraZeneca and University of Birmingham we will conduct a randomised, blinded, clinical study (24 patients) to look at the effectiveness, safety and side effects of AZD4017 in the treatment of IIH. Patients will undergo a series of investigations to assess brain pressure (through a lumbar puncture), vision and headaches at the start and end of the 3 month study. We will also be conducting regular monitoring of urine and blood alongside detailed patient assessments to evaluate drug safety and side effects.
This will be the first study to investigate the role of 11beta-HSD1 inhibitors in IIH and has the potential to offer a novel treatment in this condition which can cause blindness. Additionally, if effective, AZD4017 may have uses in other neurological conditions where the morbidity is related to elevated brain pressure.

Technical Summary

Idiopathic intracranial hypertension (IIH), is a common condition of unknown aetiology affecting the young obese female population (20 per 100,000). Faced with the global obesity epidemic, its incidence is expected to rise further. IIH is characterised by elevated intracranial pressure (ICP) which manifests as disabling headaches and severe visual loss in up to 25% of patients. An evidence base for treatment has not been established and there are currently no effective and tolerable pharamcotherapeutic options. Based upon our in-vitro observations, we have hypothesised that increased local glucocorticoid generation through the activity of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) within the choroid plexus that generates cerebrospinal fluid (excess production leading to raised ICP) is crucial to the pathogenesis of IIH. This mechanism is analogous to that occurring in the ocular ciliary body which produces aqueous humor where 11beta-HSD1 inhibitors have been shown to lower intraocular pressure. We have recently published a seminal study in patients with IIH and demonstrated that weight loss significantly reduced 11beta-HSD1 activity, ICP and dramatically improved patient symptoms; the observed reduction in ICP correlated directly with the reduction in ICP.

In collaboration with our industrial partner, AstraZeneca (AZ), we will conduct a double blind, placebo controlled randomised phase II study to assess the tolerability, safety and efficacy of the selective 11beta-HSD1 inhibitor, AZD4017, in the treatment of IIH. The study will be conducted at University Hospitals Birmingham NHS Foundation Trust, the Midlands Eye Centre and the Wellcome Trust Clinical Research Facility. In total, 24 patients with active chronic IIH (raised ICP and papilloedema) will be randomised to AZD4017 or placebo tablets (1:1).The primary outcome measure, intracranial pressure, will be evaluated by lumbar puncture at 12 weeks compared to baseline.

Planned Impact

Over the last 2 decades, the investigators on this proposal have established glucocorticoid regeneration through the activity of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) as a therapeutic target in many conditions including idiopathic intracranial hypertension (IIH). They have published many of the seminal studies in the highest impact journals (Lancet, JCI, BMJ, Nature Genetics). Reflecting the impact of their work, in 2011, 11beta-HSD1 ranked as the 2nd most popular pharmaceutical drug target in terms of number of patents filed (>40 US patents, >90 EU patents). They have now established a unique academic-industrial collaboration between University of Birmingham and AstraZeneca (AZ) to trial the selective 11beta-HSD1 inhibitor, AZD4017 in a defined population of patients with IIH. Within this collaboration, AZ have provided the active compound and placebo as well as all relevant preclinical and phase I clinical data to facilitate study design based upon the academic hypothesis. Complementing this, UoB have brought clinical trial expertise and state-of-the-art methodologies combining neurology, ophthalmology and endocrinology. The close working relationship between University Hospital Birmingham NHS trust and the Birmingham and Midlands Eye Centre which together provide one of the largest IIH services in the country will ensure that sufficient patients are recruited through the dedicated neuro-ophthalmology clinics.
On a global level, the impact of this successful collaboration between UoB and AZ will serve as a model for other academic institutions and pharmaceutical company interactions and it is hoped that this will be adopted nationally and internationally. There are clear additional benefits of these collaborations for patients and non-academics. Patients will have the potential access to new and emerging treatments sooner than would otherwise have been possible. Furthermore, it provides the opportunity to consider indications for drug therapy that may not have been considered by the pharmaceutical company.
The specific academic impact is clear and this proposal will add significantly to the field representing the first clinical trial of this class of drug in patients with IIH. Positive results from this study targeting glucocorticoid metabolism will undoubtedly pave the way for future drug development. The impact upon patient care has the potential to be equally impressive offering a new treatment in a condition where currently proven efficacious pharmacotherapies are lacking.
In conclusion, this proposal is one of the crucial chapters in the '11beta-HSD1 story' that has developed from target identification and validation through to drug development and now to trials in disease populations. It is this final component that adds the greatest impact both academically, but perhaps more importantly to patients with the aim of improving health care.

Publications

10 25 50

publication icon
Dineen R (2017) Acromegaly. in QJM : monthly journal of the Association of Physicians

 
Guideline Title Idiopathic intracranial hypertension: consensus guidelines on management.
Description IIH Clinical Guidelines
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact These were the first ever consensus guidelines on treating IIH and are the top read article on JNNP over the last 6 months. They have been read by members othe public as well as clinicians, across the UK, Europe, North and South America and other countries. The benefits should be improved quality of life for IIH patients, and improvements in clinical treatment, including less unnecessary procedures.
URL https://jnnp.bmj.com/content/89/10/1088
 
Description Impacted on how IIH is treated internationally (following IIH weight trial) - data presented in presenttions and numerous review papers
 
Description Drummond Foundation
Amount £30,000 (GBP)
Organisation Drummond Foundation 
Start 01/2017 
End 12/2020
 
Description Midland Neuroscience Teaching & Research Fund consumables funds
Amount £38,320 (GBP)
Organisation Midland Neuroscience Teaching and Research Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2020
 
Description • Midland Neuroscience Teaching & Research Fund
Amount
Organisation Midland Neuroscience Teaching and Research Fund 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Title IIH:Life 
Description  
Type Of Material Database/Collection of data 
Provided To Others? No  
 
Description Copenhagen - advance in vitro work 
Organisation University of Copenhagen
Country Denmark 
Sector Academic/University 
PI Contribution Advance in vitro work to develop new candidate drugs to treat IIH. Their PhD student was trained in my lab.
Collaborator Contribution Advance in vitro work to develop new candidate drugs to treat IIH. My post doc attended their lab for training.
Impact Funding applications and ongoing in vivo studies. Lab members regularly traveling to their centre. Joint papers. Research outputs. yearly collaborative meetings. Regular skype meetings. Joint grant applications - the Lundbeck Foundation
Start Year 2013
 
Description Intracranial pressure animal models 
Organisation Washington University School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Contribution to joint publications
Collaborator Contribution They trained our phd student in ICP MRI technique
Impact Joint publication on hydrocephalus; raised ICP studies
Start Year 2016
 
Description OCT interpretation and artificial intelligence to identify papilloedema and raised ICP 
Organisation Moorfields Eye Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Discussion on using OCT visual imaging for papilloedema with the insights from out group-developed novel analysis paradigm
Collaborator Contribution Dr Pearse Keane has aided in assessing the quality of and giving advice on the interpretation of optical coherence tomography, which has improved assessments used in both IIH:WT and IIH:DT trials. Further, he has expertise on OCT imaging and developed ideas on imaging sequences with us for papilloedema
Impact Multi-disciplinary - ophthalmology / neurology. Joint publication.
Start Year 2015
 
Description UK IIH Research Network 
Organisation Gloucestershire Royal Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Description UK IIH Research Network 
Organisation King's College Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Description UK IIH Research Network 
Organisation Leicester General Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Description UK IIH Research Network 
Organisation NHS Greater Glasgow and Clyde (NHSGGC)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Description UK IIH Research Network 
Organisation Royal Hallamshire Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Description UK IIH Research Network 
Organisation Royal Stoke University Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Description UK IIH Research Network 
Organisation The Walton Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials. This has involved: o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist) o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist) o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist) o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist) Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).
Collaborator Contribution They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.
Impact Multi-discplinary - neurology and ophthalmology
Start Year 2015
 
Title IIH:DT RCT (• Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the therapeutic efficacy and safety of an 11ß-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017)) 
Description  
Type
 
Description BMJ talk medicine 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Following the development of the first ever guidelines for the investigation and management of idiopathic intracranial hypertension, Dr Sinclair discussed them with the JNNP podcast on "BMJ talk medicine". This podcast has been listened to over 1000 times and has helped to spread the publication of these guidelines, which will directly impact and improve patient treatment in the UK and beyond.
Year(s) Of Engagement Activity 2018
URL https://soundcloud.com/bmjpodcasts/idiopathic-intracranial-hypertension-guidelines-for-diagnosis-and...
 
Description CSF symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Supervised PhD student Keira Markey presented "Phase II Study to Assess the Efficacy and Safety of an 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in Idiopathic Intracranial Hypertension: IIH:DT". The impact of this was to generate interest in the forthcoming publication of these results.
Year(s) Of Engagement Activity 2018
 
Description GLP-1 Press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact A press release by the University of Birmingham on the use of Exendin-4 was taken up by international media outlets from UK to Australia to India. The press release described research on this drug and it's affect on brain pressure by Dr Sinclair and reached a potential audience of over 3,000,000. This generated positive press for Dr Sinclair, University of Birmingham and funders NIHR.
Year(s) Of Engagement Activity 2017
URL https://www.medscape.com/viewarticle/884659
 
Description Glasgow Southern General Hospital Oct 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Informing, generated discussion and question

Increased interest in clinical trial portfolio
Year(s) Of Engagement Activity 2015
 
Description Head of the Cerebrospinal Fluid Disorders Research Group, University of Birmingham 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Regular working group (quarterly) and dicussions to enhance collaborations (local and international)

organising visiting professors from USA to teach skills and write collaborative grants
Year(s) Of Engagement Activity 2012
 
Description IIH Guidelines 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact University of Birmingham and University Hospitals Birmingham issued the press release "New guidelines aim to improve diagnosis and treatment for condition that can leave young women blind" to publicise the first ever guidelines for the treatment of IIH.
Year(s) Of Engagement Activity 2018
URL https://www.birmingham.ac.uk/university/colleges/mds/news/2018/10/brain-pressure-guidelines.aspx
 
Description IIH JLA 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact I led a James Lind Alliance Priority Setting Partnership in IIH with patients, carers, and clinicians to identify the top 10 research priorities for further research.

This has given support for future research directions.
Year(s) Of Engagement Activity 2016,2017,2018
 
Description IIH UK Patient charity talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact The presentation resulted in a substantial question and answer session with discussion from the audience. Afterwards, the trials team were approached for information on the trials, including information on how to participate, with some patients giving details to be contacted by the team to take part.

After this patient conference the trials team received an increased number of requests for information about or participation in their trials. The trials websites received increased traffic after the conference (doubled in June 2015).
Year(s) Of Engagement Activity 2015
URL http://www.iih.org.uk/index.php?option=com_content&view=article&id=91
 
Description IIH UK national patient conference June 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Informing, generated discussion and questions from patients:
• Invited speaker at the IIH UK national patient conference June 2015, Birmingham, UK.

generated interest and enquiries to participate in our clinical trial portfolio
Year(s) Of Engagement Activity 2015
 
Description IIH:DT presentation at West Midlands CSF Dysorders Symposium 2014 
Form Of Engagement Activity
Part Of Official Scheme? No
Primary Audience
Year(s) Of Engagement Activity
 
Description IIHUK - Top 10 IIH patient questions video series 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact With the patient charity IIHUK I produced a series of videos available on youtube and the charity's site discussing the top 10 (chosen by patients) questions in IIH. This has helped patients understand their condition and has informed patient choice on treatment options.
Year(s) Of Engagement Activity 2017
URL https://www.youtube.com/channel/UCEpwmN0MWtQ-6hRSL4A1Vpw
 
Description IIHUK Information Sheet authoring and approval 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact I produced the IIHUK patient information sheets for the charity's websites. This has helped patients understand their condition and has informed patient choice on treatment options.
Year(s) Of Engagement Activity 2018
URL https://www.iih.org.uk/leaflets
 
Description Midlands Neurology 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Supervised PhD student Keira Markey presented "Phase II Study to Assess the Efficacy and Safety of an 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in Idiopathic Intracranial Hypertension: IIH:DT" and won best research presentation (Michael Jepherson award). The impact of this was to generate interest in the forthcoming publication of these results.
Year(s) Of Engagement Activity 2018
 
Description Migraine Trust International Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Supervised PhD student Keira Markey presented "Phase II Study to Assess the Efficacy and Safety of an 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in Idiopathic Intracranial Hypertension: IIH:DT" and won first prize for platform presentation, winning the trainee excellence award. The impact of this was to generate interest in the forthcoming publication of these results.
Year(s) Of Engagement Activity 2018
 
Description Patron of IIH UK patient charity 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Being patron of the main IIH patient charity in the UK has led to closer collaboration with the charity. This has led to their involvement in Patient and Public Involvement aspects of my trials, and to their help with publicising the trials.

I have been able to work with the charity trustees to suggest direction for research, and have received their help in patient surveys to preview/inform research questions, for example.

We have had patients contact the trials team to then take part in the trials that we would not have otherwise reached. The trials website receive more traffic when the charity's promotion of them/the trials is more active.
Year(s) Of Engagement Activity 2014,2015
URL http://www.iih.org.uk
 
Description • Chair and Invited Speaker at the European Neuro-Ophthalmology Society Conference, Oxford, UK. 11/04/13 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Invited to Chaired a morning session and organised the speaker list. Then invited to present my research on Idiopathic Intracranial Hypertension

Oxford, UK. 11/04/13
title: Obesity and the Female Brain: a High Pressure situation!

Multiple offers of collaboarion internationally
Year(s) Of Engagement Activity 2013
 
Description • Invited Speaker at UK Neuro-Ophthalmology Special Interest Group Conference, Glasgow. 13/03/13 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Conference - UK Neuro-Ophthalmology
Title: Idiopathic Intracranial Hypertension: What do we need to know......?
Glasgow. 13/03/13

Collaborations and dissemination of research findings
Year(s) Of Engagement Activity 2013